Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus
- PMID: 23475956
- DOI: 10.1158/1535-7163.MCT-12-0811
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus
Abstract
A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), was tested in nasopharyngeal carcinoma (NPC), both in vitro and in vivo. Dose-response of different concentrations of bortezomib and SAHA on inhibition of cell proliferation of NPC was determined. Mechanisms of apoptosis and effects on lytic cycle activation of Epstein-Barr virus (EBV) were investigated. Combination of bortezomib and SAHA (bortezomib/SAHA) synergistically induced killing of a panel of NPC cell lines. Pronounced increase in sub-G1, Annexin V-positive, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cell populations were detected after treatment with bortezomib/SAHA when compared with either drug alone. Concomitantly, markedly augmented proteolytic cleavage of PARP, caspase-3, -7, -8, and -9, reactive oxygen species (ROS) generation, and caspase-8-dependent histone acetylation were observed. ROS scavenger, N-acetyl cysteine, diminished the apoptotic effects of bortezomib/SAHA, whereas caspase inhibitor Z-VAD-FMK significantly suppressed the apoptosis without decreasing the generation of ROS. Bortezomib inhibited SAHA's induction of EBV replication and abrogated production of infectious viral particles in NPC cells. Furthermore, bortezomib/SAHA potently induced apoptosis and suppressed the growth of NPC xenografts in nude mice. In conclusion, the novel drug combination of bortezomib and SAHA is highly synergistic in the killing of NPC cells in vitro and in vivo. The major mechanism of cell death is ROS-driven caspase-dependent apoptosis. Bortezomib antagonizes SAHA's activation of EBV lytic cycle in NPC cells. This study provides a strong basis for clinical testing of the combination drug regimen in patients with NPC.
©2013 AACR
Similar articles
-
Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.Int J Cancer. 2012 Oct 15;131(8):1930-40. doi: 10.1002/ijc.27439. Epub 2012 Mar 8. Int J Cancer. 2012. PMID: 22261816
-
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.Eur J Haematol. 2008 Feb;80(2):133-42. doi: 10.1111/j.1600-0609.2007.00995.x. Epub 2007 Dec 20. Eur J Haematol. 2008. PMID: 18005386
-
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.Br J Haematol. 2014 Dec;167(5):639-50. doi: 10.1111/bjh.13089. Epub 2014 Aug 25. Br J Haematol. 2014. PMID: 25155625
-
Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies.Curr Opin Oncol. 2011 Sep;23(5):482-7. doi: 10.1097/CCO.0b013e3283499c37. Curr Opin Oncol. 2011. PMID: 21788895 Free PMC article. Review.
-
The Efficacy of Natural Bioactive Compounds for the Treatment of Nasopharyngeal Carcinoma.Mini Rev Med Chem. 2021;21(13):1679-1691. doi: 10.2174/1389557521666210105113831. Mini Rev Med Chem. 2021. PMID: 33402084 Review.
Cited by
-
ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.Oxid Med Cell Longev. 2020 Jul 22;2020:5047987. doi: 10.1155/2020/5047987. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32774675 Free PMC article. Review.
-
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.Oncogene. 2019 Oct;38(41):6737-6751. doi: 10.1038/s41388-019-0912-5. Epub 2019 Aug 12. Oncogene. 2019. PMID: 31406244
-
Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 disease severity.bioRxiv [Preprint]. 2020 Sep 13:2020.09.13.276923. doi: 10.1101/2020.09.13.276923. bioRxiv. 2020. Update in: Sci Adv. 2021 Aug 18;7(34):eabf8609. doi: 10.1126/sciadv.abf8609 PMID: 32935109 Free PMC article. Updated. Preprint.
-
Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.Int J Mol Sci. 2021 Mar 10;22(6):2802. doi: 10.3390/ijms22062802. Int J Mol Sci. 2021. PMID: 33802143 Free PMC article. Review.
-
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.Oncotarget. 2016 Jun 21;7(25):37966-37978. doi: 10.18632/oncotarget.9274. Oncotarget. 2016. PMID: 27177225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials